Divestiture and Sale of Zohydro ER business (Tables)

12 Months Ended

Dec. 31, 2017

Zohydro ER [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Net Assets and Calculation of the Gain on Sale

The following table summarizes the results of discontinued operations presented in the consolidated statements of operations for the periods indicated (in thousands):

	Year Ended December 31,
Discontinued operations	2017			2016			2015
Net product revenue	$	57		$	532		$	11,299
Operating expense (income):
Cost of product sold	—			15			2,205
Royalty expense	3			32			835
Research and development	—			—			5,504
Selling, general and administrative	920			1,594			14,820
Restructuring expense	—			—			588
Gain on sale of business	—			—			(89,484		)
Total operating expense (income)	923			1,641			(65,532		)
Other income	—			—			5,077
Net (loss) income from discontinued operations before tax	(866		)	(1,109		)	81,908
Tax benefit (expense)	71			88			(14,060		)
Net loss (income) from discontinued operations	$	(795	)	$	(1,021	)	$	67,848